Ketanserin

Phase 3Small molecule

UUniversity Hospital, Basel, Switzerland

Ketanserin is one of 88 small molecule programs targeting Sepsis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

SepsisActive, not recruiting

Kidney FailureActive, not recruiting

Diabetic FootActive, not recruiting

SepsisPhase 3

Active, not recruiting

Kidney FailurePhase 3

Active, not recruiting

Diabetic FootPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

308 competitors in Sepsis

#DrugCompanyPhaseTrials

Ketanserin

UUniversity Hospital, Basel, Switzerland

Phase 3

1 2

Corlanor

Amgen

Preclinical

2 3

Simdax

Orion Corporation, Orion Pharma

Preclinical

1 4

Primaxin

Zyvox

Zemplar

Brevibloc

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

3 8

Levophed

GGeneral Hospital of Ningxia Medical University

Preclinical

2 9

Epsom Salt

FFresenius Kabi Oncology Ltd.

Preclinical

1 10

Aquasol a

BBandim Health Project

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2030

Phase 1Recruiting

Study completion

NCT03289949

Clinical

Trials by Indication[1]

Diabetic Foot1 trial

Efficacy of Pirfenidone Plus MODD in Diabetic Foot Ulcers

Completed·UUniversity of Guadalajara·Phase 1/2·NCT02632877·60 enrolled

Sepsis1 trial

The Effect of Ketanserin on the Microcirculation in Sepsis

Completed·FFrisius Medisch Centrum·Phase 3·NCT01329887·10 enrolled

LSD1 trial

Effect of Ketanserin After LSD Administration

Completed·UUniversity Hospital, Basel, Switzerland·Phase 1·NCT04558294·24 enrolled

Kidney Failure1 trial

Fenoldopam and Ketanserin for Acute Kidney Failure Prevention After Cardiac Surgery

Terminated·MMedical University of Gdansk·Phase 3·NCT00557219·60 enrolled

Unspecified3 trials

Ketanserin Effects on Peripheral Temperature and Lactate

Unknown status·OOnze Lieve Vrouwe Gasthuis·Phase 4·NCT03646318·120 enrolled

The Neurobiological Effect of 5-HT2AR Modulation

Recruiting·GGitte Moos Knudsen·Phase 1·NCT03289949·200 enrolled

The Role of 5-HT2A Receptor in the Perception of Self and Personal Meaning in Healthy Volunteers

Completed·PPsychiatric University Hospital, Zurich·N/A·NCT02451072·25 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Ketanserin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ketanserin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ketanserin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital, Basel, Switzerland company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity Hospital, Basel, Switzerland

Ketanserin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2030

Trials by Indication[1]

Diabetic Foot1 trial

Sepsis1 trial

LSD1 trial

Kidney Failure1 trial

Unspecified3 trials

References

Drug Info

Quick Facts

Related News